Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.

Koutaro YokoteMisako SanoIsao TsumiyamaDeborah Keefe

Published in: Diabetes, obesity & metabolism (2020)

Dual inhibition of SGLT1/2 with licogliflozin treatment induced a dose-dependent reduction in body weight in Japanese patients with obesity. Treatment with licogliflozin was safe and well tolerated in this study. The study is registered with ClinicalTrials.gov (NCT03320941).

Keyphrases

body weight
metabolic syndrome
type diabetes
insulin resistance
physical activity
body mass index
oxidative stress
skeletal muscle
endothelial cells
high glucose